Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLNN
stocks logo

CLNN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
37.86K
-58.4%
-0.559
-66.55%
71.67K
-11.52%
-0.523
+481.48%
71.67K
+165.44%
-0.587
-24.79%
Estimates Revision
The market is revising No Change the revenue expectations for Clene Inc. (CLNN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 4.31%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.2%
In Past 3 Month
Stock Price
Go Up
up Image
+4.31%
In Past 3 Month
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 28.40 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 28.40 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.290
sliders
Low
20.00
Averages
28.40
High
31.00
Current: 6.290
sliders
Low
20.00
Averages
28.40
High
31.00
Maxim
Naz Rahman
Buy
maintain
$20 -> $30
2025-12-03
New
Reason
Maxim
Naz Rahman
Price Target
$20 -> $30
2025-12-03
New
maintain
Buy
Reason
Maxim analyst Naz Rahman raised the firm's price target on Clene to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which "clears way" for an NDA filing, the analyst says.
Benchmark
Buy
downgrade
$33 -> $31
2025-09-10
Reason
Benchmark
Price Target
$33 -> $31
2025-09-10
downgrade
Buy
Reason
Benchmark lowered the firm's price target on Clene to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm's model.
Canaccord
Buy
downgrade
$83 -> $48
2025-08-18
Reason
Canaccord
Price Target
$83 -> $48
2025-08-18
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Clene to $48 from $83 and keeps a Buy rating on the shares. The firm updated its model following Q2 results but admits clarity from the FDA on its ability to file for accelerated approval or not for its ALS and Ms drugs are the key. They now include contributions from ALS and MS at probabilities of approval of 33% and 20%, respectively in their model.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$30
2025-04-23
Reason
Jones Trading
Justin Walsh
Price Target
$30
2025-04-23
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$31
2025-04-08
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$31
2025-04-08
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$23
2025-04-08
Reason
D. Boral Capital
Jason Kolbert
Price Target
$23
2025-04-08
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Clene Inc (CLNN.O) is -2.70, compared to its 5-year average forward P/E of -5.38. For a more detailed relative valuation and DCF analysis to assess Clene Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.38
Current PE
-2.70
Overvalued PE
1.64
Undervalued PE
-12.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.57
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.41
Undervalued EV/EBITDA
-2.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
449.73
Current PS
0.00
Overvalued PS
929.17
Undervalued PS
-29.72
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 270.86% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 270.86% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CLNN News & Events

Events Timeline

(ET)
2025-12-03
08:20:00
Clene Completes Biomarker Analyses for ALS Treatment CNM-Au8
select
2025-11-13 (ET)
2025-11-13
08:10:01
Clene anticipates funding to last until the second quarter of 2026.
select
2025-11-13
08:09:13
Clene Announces Q3 Earnings Per Share of 85 Cents, Exceeding Consensus Estimate of 56 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedClene Set to Deliver Important Update on CNM-Au8 for Amyotrophic Lateral Sclerosis

  • Clene Inc. Update: Clene Inc. will provide an update on its CNM-Au8 program for amyotrophic lateral sclerosis (ALS) on December 3, 2025, as it develops a gold nanocrystal suspension aimed at treating ALS, Multiple Sclerosis, and Parkinson's Disease.

  • HEALEY ALS Platform Trial: The ongoing HEALEY ALS Platform Trial is assessing the safety and efficacy of CNM-Au8 in ALS patients, with initial results indicating no improvement in disease progression over 24 weeks, but a post-hoc analysis showed a significant survival advantage for the CNM-Au8 group.

  • FDA Submission Plans: Clene plans to submit a New Drug Application for CNM-Au8 in ALS in the first quarter of 2026, following the completion of ALS biomarker data analyses in accordance with FDA recommendations.

  • Stock Performance: Clene's stock has fluctuated between $2.28 and $13.50 over the past year, closing at $9.26, down 3.14% in the latest trading session.

[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
5.0
12-03Globenewswire
Clene Inc. to Update ALS Treatment Progress on December 3, 2025
  • Investor Call Announcement: Clene Inc. plans to host an investor call on December 3, 2025, at 8:30 AM ET to provide updates on its CNM-Au8 program for amyotrophic lateral sclerosis (ALS), aiming to bolster investor confidence in its research direction.
  • Clinical Stage Progress: As a late clinical-stage biopharmaceutical company, Clene's CNM-Au8 project focuses on protecting neurons by improving mitochondrial function, which is expected to offer new treatment options for ALS patients, highlighting significant market potential.
  • Webcast Accessibility: The meeting will be accessible via a webcast, allowing investors to participate through the company’s website link, enhancing transparency and fostering interaction with investors, which is likely to attract more attention.
  • Company Background: Based in Salt Lake City, Clene Inc. is dedicated to improving mitochondrial health and developing innovative therapies for diseases like ALS and multiple sclerosis, demonstrating its strategic positioning in the biopharmaceutical sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Clene Inc (CLNN) stock price today?

The current price of CLNN is 6.29 USD — it has decreased -12.88 % in the last trading day.

arrow icon

What is Clene Inc (CLNN)'s business?

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.

arrow icon

What is the price predicton of CLNN Stock?

Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 28.40 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Clene Inc (CLNN)'s revenue for the last quarter?

Clene Inc revenue for the last quarter amounts to 15.00K USD, decreased -82.76 % YoY.

arrow icon

What is Clene Inc (CLNN)'s earnings per share (EPS) for the last quarter?

Clene Inc. EPS for the last quarter amounts to -0.85 USD, decreased -30.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Clene Inc (CLNN)'s fundamentals?

The market is revising No Change the revenue expectations for Clene Inc. (CLNN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 4.31%.
arrow icon

How many employees does Clene Inc (CLNN). have?

Clene Inc (CLNN) has 75 emplpoyees as of December 05 2025.

arrow icon

What is Clene Inc (CLNN) market cap?

Today CLNN has the market capitalization of 65.00M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free